- Home
- HCVI vs VIGL Comparison
HCVI vs VIGL Comparison
Compare HCVI & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCVI
- VIGL
- Stock Information
- Founded
- HCVI 2021
- VIGL 2020
- Country
- HCVI United States
- VIGL United States
- Employees
- HCVI N/A
- VIGL N/A
- Industry
- HCVI Blank Checks
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- HCVI Finance
- VIGL Health Care
- Exchange
- HCVI Nasdaq
- VIGL Nasdaq
- Market Cap
- HCVI 176.6M
- VIGL 148.7M
- IPO Year
- HCVI 2021
- VIGL 2022
- Fundamental
- Price
- HCVI $10.67
- VIGL $3.57
- Analyst Decision
- HCVI
- VIGL Buy
- Analyst Count
- HCVI 0
- VIGL 5
- Target Price
- HCVI N/A
- VIGL $16.60
- AVG Volume (30 Days)
- HCVI 37.5K
- VIGL 80.1K
- Earning Date
- HCVI 01-01-0001
- VIGL 08-13-2024
- Dividend Yield
- HCVI N/A
- VIGL N/A
- EPS Growth
- HCVI N/A
- VIGL N/A
- EPS
- HCVI N/A
- VIGL N/A
- Revenue
- HCVI N/A
- VIGL N/A
- Revenue This Year
- HCVI N/A
- VIGL N/A
- Revenue Next Year
- HCVI N/A
- VIGL N/A
- P/E Ratio
- HCVI N/A
- VIGL N/A
- Revenue Growth
- HCVI N/A
- VIGL N/A
- 52 Week Low
- HCVI $10.30
- VIGL $2.47
- 52 Week High
- HCVI $11.47
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- HCVI 62.64
- VIGL 48.93
- Support Level
- HCVI $10.62
- VIGL $3.66
- Resistance Level
- HCVI $10.66
- VIGL $4.03
- Average True Range (ATR)
- HCVI 0.01
- VIGL 0.29
- MACD
- HCVI 0.00
- VIGL 0.03
- Stochastic Oscillator
- HCVI 100.00
- VIGL 44.58
About HCVI Hennessy Capital Investment Corp. VI
Hennessy Capital Investment Corp VI is a shell company.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.